MedTrace Logo

Intravenous Immunoglobulins in Complex-regional Pain Syndrome

NCT00949065 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-07-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether intravenous immunoglobulins are effective in the treatment of complex-regional pain syndrome.

Conditions

  • Complex Regional Pain Syndrome Type 1

Interventions

BIOLOGICAL

intravenous immunoglobulins

0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks

Sponsors & Collaborators

  • University of Giessen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-01-31
Completion
2011-02-15

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00949065 on ClinicalTrials.gov